JAGX insider transaction filings
Jaguar Health, Inc. — 45 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-03-12. Screen JAGX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for JAGX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Jaguar Health, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-03-12 | 4 | MICEK JOHN — Director | Grant/award (A): 7,377 @ $0 · Grant/award (A): 7,377 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | King Steven R. — See Remarks | Grant/award (A): 11,740 @ $0 · Grant/award (A): 11,740 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | Wolin Jonathan S. — See Remarks | Grant/award (A): 11,740 @ $0 · Grant/award (A): 11,740 (derivative) @ $0 | EDGAR |
| 2026-01-21 | 4 | CONTE LISA A — See Remarks, Director | Grant/award (A): 28,592 @ $0 · Grant/award (A): 28,592 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Chaturvedi Pravin R — Chief Scientific Officer | Grant/award (A): 11,740 @ $0 · Grant/award (A): 11,740 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Siegel Jonathan B. — Director | Grant/award (A): 7,377 @ $0 · Grant/award (A): 7,377 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Jayasuriya Anula — Director | Grant/award (A): 5,870 @ $0 · Grant/award (A): 5,870 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | Lizak Carol R. — Chief Financial Officer | Grant/award (A): 11,740 @ $0 · Grant/award (A): 11,740 (derivative) @ $0 | EDGAR |
| 2025-12-15 | 4 | BOCHNOWSKI JAMES J — Director | Grant/award (A): 6,363 @ $0 · Grant/award (A): 6,363 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | Siegel Jonathan B. — Director | Disposition to issuer (D): 9,000 (derivative) @ $50,000 · Grant/award (A): 9,462 (derivative) @ $50,000 · Grant/award (A): 18,262 (derivative) | EDGAR |
| 2025-06-26 | 4 | King Steven R. — See Remarks | Disposition to issuer (D): 3,600 (derivative) @ $20,000 · Grant/award (A): 3,785 (derivative) @ $20 · Grant/award (A): 7,304 (derivative) | EDGAR |
| 2025-06-26 | 4 | Chaturvedi Pravin R — Chief Scientific Officer | Disposition to issuer (D): 3,600 (derivative) @ $20,000 · Grant/award (A): 3,785 (derivative) @ $20,000 · Grant/award (A): 7,304 (derivative) | EDGAR |
| 2025-06-26 | 4 | Wolin Jonathan S. — See Remarks | Disposition to issuer (D): 9,000 (derivative) @ $50,000 · Grant/award (A): 9,462 (derivative) @ $50,000 · Grant/award (A): 18,262 (derivative) | EDGAR |
| 2025-06-26 | 4 | BOCHNOWSKI JAMES J — Director | Disposition to issuer (D): 27,002 (derivative) @ $150,000 · Grant/award (A): 28,388 (derivative) @ $150,000 · Grant/award (A): 54,786 (derivative) | EDGAR |
| 2025-06-26 | 4 | MICEK JOHN — Director | Disposition to issuer (D): 9,000 (derivative) @ $50,000 · Grant/award (A): 9,462 (derivative) @ $50,000 · Grant/award (A): 18,262 (derivative) | EDGAR |
| 2025-06-26 | 4 | CONTE LISA A — CEO and President, Director | Disposition to issuer (D): 9,000 (derivative) @ $50,000 · Grant/award (A): 9,462 (derivative) @ $50,000 · Grant/award (A): 18,262 (derivative) | EDGAR |
| 2025-05-20 | 4 | King Steven R. — See Remarks | Option exercise (M): 1 · Option exercise (M): 1 (derivative) @ $0 | EDGAR |
| 2025-05-20 | 4 | CONTE LISA A — CEO and President, Director | Option exercise (M): 2 · Option exercise (M): 2 (derivative) @ $0 | EDGAR |
| 2025-04-02 | 4 | King Steven R. — See Remarks | Purchase (P): 3,600 (derivative) @ $20,000 · Purchase (P): 3,600 (derivative) | EDGAR |
| 2025-04-02 | 4 | Siegel Jonathan B. — Director | Purchase (P): 9,000 (derivative) @ $50,000 · Purchase (P): 9,000 (derivative) | EDGAR |
| 2025-04-02 | 4 | Chaturvedi Pravin R — Chief Scientific Officer | Purchase (P): 3,600 (derivative) @ $20,000 · Purchase (P): 3,600 (derivative) | EDGAR |
| 2025-04-02 | 4 | Wolin Jonathan S. — See Remarks | Purchase (P): 9,000 (derivative) @ $50,000 · Purchase (P): 9,000 (derivative) | EDGAR |
| 2025-04-02 | 4 | Lizak Carol R. — Chief Financial Officer | Purchase (P): 5,400 (derivative) @ $30,000 · Purchase (P): 5,400 (derivative) | EDGAR |
| 2025-04-02 | 4 | BOCHNOWSKI JAMES J — Director | Purchase (P): 27,002 (derivative) @ $150,000 · Purchase (P): 27,002 (derivative) | EDGAR |
| 2025-04-02 | 4 | MICEK JOHN — Director | Purchase (P): 9,000 (derivative) @ $50,000 · Purchase (P): 9,000 (derivative) | EDGAR |
| 2025-04-02 | 4 | CONTE LISA A — CEO and President, Director | Purchase (P): 9,000 (derivative) @ $50,000 · Purchase (P): 9,000 (derivative) | EDGAR |
| 2024-10-10 | 4 | Lizak Carol R. — Chief Financial Officer | Grant/award (A): 4,280 @ $0 · Grant/award (A): 34,240 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | Chaturvedi Pravin R — Chief Scientific Officer | Grant/award (A): 4,922 @ $0 · Grant/award (A): 39,376 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | Wolin Jonathan S. — See Remarks | Grant/award (A): 4,922 @ $0 · Grant/award (A): 39,376 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | Jayasuriya Anula — Director | Grant/award (A): 21,000 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | King Steven R. — See Remarks | Grant/award (A): 4,922 @ $0 · Grant/award (A): 39,376 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | Siegel Jonathan B. — Director | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | BOCHNOWSKI JAMES J — Director | Grant/award (A): 23,200 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | MICEK JOHN — Director | Grant/award (A): 26,500 (derivative) @ $0 | EDGAR |
| 2024-10-10 | 4 | CONTE LISA A — See Remarks, Director | Grant/award (A): 16,503 @ $0 · Grant/award (A): 132,020 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Chaturvedi Pravin R — Chief Scientific Officer | Option exercise (M): 871 · Option exercise (M): 871 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Wolin Jonathan S. — Chief of Staff, CCO & GC | Option exercise (M): 871 · Option exercise (M): 871 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | Lizak Carol R. — Chief Financial Officer | Option exercise (M): 431 · Option exercise (M): 431 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | King Steven R. — See Remarks | Option exercise (M): 612 · Option exercise (M): 612 (derivative) @ $0 | EDGAR |
| 2024-05-21 | 4 | CONTE LISA A — CEO and President, Director | Option exercise (M): 2,695 · Option exercise (M): 2,695 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Chaturvedi Pravin R — Chief Scientific Officer | Option exercise (M): 134 · Grant/award (A): 134 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Wolin Jonathan S. — Chief of Staff, CCO & GC | Option exercise (M): 89 · Grant/award (A): 89 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Lizak Carol R. — Chief Financial Officer | Option exercise (M): 60 · Grant/award (A): 60 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | King Steven R. — See Remarks | Option exercise (M): 178 · Grant/award (A): 178 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | CONTE LISA A — CEO and President, Director | Option exercise (M): 600 · Grant/award (A): 600 (derivative) @ $0 | EDGAR |
Recent 8-K events — Jaguar Health, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-21 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-15 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-04 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-08-19 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-14 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-01 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-25 | 8-K | 1.01 — Entry into a Material Definitive Agreement 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K/A | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=JAGX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →